| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,607 |
7,606 |
$417K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,968 |
7,014 |
$259K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,786 |
1,656 |
$166K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,320 |
2,163 |
$133K |
| 99484 |
|
3,893 |
2,784 |
$94K |
| 80305 |
|
1,565 |
1,388 |
$38K |
| 20553 |
|
1,002 |
679 |
$27K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
187 |
176 |
$20K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
77 |
65 |
$9K |
| 96127 |
|
1,981 |
1,711 |
$8K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
527 |
464 |
$6K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
116 |
109 |
$4K |
| 96160 |
|
100 |
85 |
$774.68 |
| 99215 |
Prolong outpt/office vis |
15 |
13 |
$696.15 |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
17 |
12 |
$20.73 |
| 96130 |
|
17 |
12 |
$8.80 |
| 96138 |
|
17 |
12 |
$1.17 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
716 |
547 |
$0.06 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
326 |
250 |
$0.01 |
| 1036F |
|
327 |
251 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
54 |
42 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
54 |
42 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
57 |
45 |
$0.00 |
| 96132 |
|
17 |
12 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
791 |
602 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
777 |
594 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
566 |
437 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
511 |
394 |
$0.00 |
| 4004F |
|
55 |
43 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
17 |
12 |
$0.00 |